144 results on '"Di Bona, Eros"'
Search Results
2. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
3. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
4. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience
5. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
6. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
7. The long‐acting anti‐C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
8. Corrigendum to “Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience” [Leukemia Res. 114 (March 2022) 106803]
9. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies
10. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
11. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
12. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
13. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up
14. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
15. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
16. Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow-up
17. Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
18. MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
19. POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
20. Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
21. SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey.
22. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia
23. Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation
24. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
25. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after
26. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes
27. Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
28. Prolonged Overall Survival with Second On-Demand Autologous Transplant in Multiple Myeloma
29. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
30. The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
31. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
32. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia
33. Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies
34. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA Archive of Adult Acute Leukaemia
35. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia
36. Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma
37. Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia
38. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up
39. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience
40. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.
41. A (15;17) translocation not associated with acute promyelocytic leukaemia
42. COVID‐19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.
43. COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy
44. Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
45. Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib
46. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
47. Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia.
48. Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.a Real Life Multicentric Experience of the Northern Italy
49. What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening
50. Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the ‘NEXT-IN-CML' Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.